{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041053","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.530450+00:00","generated_at":"2026-06-02T04:57:03.293982+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties","bullets":["ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.","OncoX to pay $6.25M (or 1.25M shares at $5) within 30 days; additional $0.625M milestone after next fundraising (no guarantee).","ABVC entitled to 5% royalties on net sales, up to $12.5M; also may receive cash payments of at least $100K toward licensing fees.","Press release states aggregate expected income of $13.75M and royalties up to $12.5M, but commercialization remains uncertain.","Four FDA INDs approved for ABVC's oncology pipeline; ABV-1703 (BLEX 404) for pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041053","json":"https://secwatch.observer/filing/0001213900-24-041053.json","markdown":"https://secwatch.observer/filing/0001213900-24-041053.md","text":"https://secwatch.observer/filing/0001213900-24-041053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/0001213900-24-041053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:57:03.293982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7888140c9d3b85115ab6176b7d4973bfdab46186","claim":"ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at $6,250,000 (effective 2024-05-08).","evidence_excerpt":"ompany entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024041053/0001213900-24-041053-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"OncoX BioPharma, Inc."},{"label":"Value","value":"$6,250,000"},{"label":"Effective","value":"2024-05-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}